Key result
Low-dose subcutaneous rIL2 therapy in patients with normal left ventricular function significantly decreased LVEF from 54% to 50% (P=0.012).
Why the study?
Does low dose subcutaneous rIL2 reduce left ventricular ejection fraction in patients with renal cell carcinoma and normal LV function?
Observational (n=17)
Does low dose subcutaneous rIL2 reduce left ventricular ejection fraction in patients with renal cell carcinoma and normal LV function?
Absolute Event Rate: 50% vs 54%
p-value: p=0.012
Low-dose subcutaneous rIL2 therapy in patients with normal LV function induces a negative inotropic effect, potentially mediated by increased nitric oxide concentrations.
May warrant LVEF monitoring with low-dose rIL2; leaves open clinical relevance and need for prospective validation.
UNLABELLED: Experimental data have shown that rIL2 has negative inotropic properties. This has not been investigated in humans with normal left ventricular function. Seventeen consecutive renal cell carcinoma patients who received rIL2 therapy because of dissemination were analyzed before and after treatment with a low dose of rIL2 subcutaneously. Left ventricular ejection fraction (echocardiography), heart rate variability parameters (24 h electrocardiography), and TNF alpha, IL1 beta and nitric oxide metabolites (NO(x)) were measured. LVEF decreased from 54+/-7 to 50+/-6% (mean+/-S.D.; P=0.012), with a concomitant increase in heart rate from 87+/-13 to 94+/-13 beats/min (P=0.031). All frequency domain HRV parameters decreased: the total power from 18.0+/-7.9 to 14.0+/-5.0 ms (P=0.001), the low frequency from 10.3+/-5.4 to 8. 3+/-3.4 ms (P=0.001), and the high frequency from 6.3+/-2.6 to 4. 5+/-1.1 ms (P=0.001). There was no measurable effect on TNF alpha, IL1 beta concentrations. Plasma levels of nitrate (NO(x)) increased from 22.8+/-14.4 to 41.8+/-26.6 micromol/l (P=0.007). CONCLUSIONS: A low dose of rIL2 has a negative inotropic effect that may be mediated by increased NO concentrations. It also reduces sympathetic activity as reflected in HRV parameters.
No takes yet. Share an insight, caveat, or question.
Tio et al. (2000) conducted an observational in Renal cell carcinoma (n=17). Recombinant Interleukin 2 (rIL2) vs. Baseline (before treatment) was evaluated on Left ventricular ejection fraction (LVEF) (p=0.012). Low-dose subcutaneous rIL2 therapy in patients with normal left ventricular function significantly decreased LVEF from 54% to 50% (P=0.012).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: